Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA clears Lantheus' Tauklarify (MK-6240) for tau pathology imaging in Alzheimer's disease evaluation
Imaging agent, neurological, PET imaging, Alzheimer's disease, tau pathology - Read more

Biogen wins China approval for Jingfei (felzartamab) anti-CD38 antibody in multiple myeloma
Antibody, cancer, monoclonal antibody, multiple myeloma, CD38 target, combination therapy - Read more

Aizen Therapeutics strikes oral peptide collaboration with undisclosed San Diego biotech, $100M milestones per target
Co-development, AI/ML, oral peptides, immunology, neurology, milestone payments - Read more

Eli Lilly, OmniAb collaborate on ion channel program for up to $370M in milestones
Research collaboration, antibody, ion channel, drug discovery, milestone payments - Read more

Cognizant, Benchling selected to implement AI R&D platform at Kyowa Kirin's Japan research sites
Research collaboration, AI/ML, drug discovery, R&D, rare disease, antibody - Read more

Shanghai Henlius Biotech, Sandoz expand biosimilars collaboration covering up to 10 mAb/ADC products, $322M total payments
Strategic collaboration, biosimilars, antibody, oncology, milestone payments, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Vera Therapeutics' Trutakna shows kidney function stabilization in Ph3, rivaling Otsuka's Voyxact in immunoglobulin A nephropathy
Antibody, kidney disease, monoclonal antibody, IgA nephropathy, proteinuria, eGFR - Read more

AstraZeneca's Tagrisso (osimertinib) plus Orpathys (savolitinib) meets PFS and overall survival goals in Ph3 EGFR-mutated non-small-cell lung cancer trial
Small molecule, cancer, non-small cell lung cancer, EGFR mutation, MET amplification, antibody-drug conjugate - Read more

Argenx submits Vyvgart Hytrulo (efgartigimod) to FDA for autoimmune myositis after Ph2/3 win
Antibody, autoimmune, FcRn blocker, monoclonal antibody, myositis - Read more

Daiichi Sankyo, AstraZeneca's Enhertu (trastuzumab deruxtecan) meets Ph3 primary endpoint in first-line HER2 mutant non-small cell lung cancer
Antibody drug conjugate, cancer, non-small cell lung cancer, HER2, first-line treatment, trastuzumab deruxtecan - Read more

Silence Therapeutics closes upsized $201.3M public offering, advancing siRNA therapies
Clinical-stage, siRNA, RNA interference, rare disease - Read more

Daré Bioscience raises $6M registered direct offering, women's health biotech funding
Women's health, biotech, clinical-stage, small molecule - Read more

Slate Medicines reverse merges with Fulcrum Therapeutics, raises $245M for migraine antibody trials on Nasdaq
Monoclonal antibody, neurological, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

J&J returns lymphoma CAR T prizlon-cel to AbelZeta Pharma after $245M upfront 2023 deal
Licensing deal, oncology, cell therapy, milestone payments - Read more

AstraZeneca halts Ph3 trial of (volrustomig) in metastatic non-small cell lung cancer after interim data failure
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-L1, first-line treatment - Read more

EyePoint's duravyu (tyrosine kinase inhibitor) fails Ph3 non-inferiority vs. aflibercept in wet age-related macular degeneration
Small molecule, ophthalmology, tyrosine kinase inhibitor, wet age-related macular degeneration, VEGF pathway - Read more

Eli Lilly's Danish obesity awareness campaign draws lawmaker scrutiny over transparency concerns
GLP-1, obesity, regulatory, competitive - Read more

BioCryst Pharmaceuticals scraps internal discovery, shifts to external deals to expand rare disease pipeline
Small molecule, rare disease, strategic, operational, financial - Read more

Evaxion scraps solid tumor vaccine EVX-03 to prioritize Duke-partnered glioblastoma candidate EVX-05
DNA vaccine, oncology, strategic, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here